Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
”Very nice and comprehensive review on liquid biopsy for Cancer published in JAMA.
ctDNA, consisting of small DNA fragments from cancer cells that can be analyzed in human blood, can help clinicians monitor cancer progression, detect minimal residual cancer, and identify genetic variants that may help guide treatment decisions.
Use of ctDNA may help select best treatment and timing of therapy for a patient with cancer, but optimal clinical applications remain unclear.”
Title: Liquid Biopsies for CancerA Translational Science Review
Authors: Jessica Mezzanotte-Sharpe, Katrina Piemonte, Ben H. Park
Other articles featuring Vivek Subbiah on OncoDaily.